Top Markets
Coin of the day
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Ранг среди акций #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Цена акции
$2.35
Последняя синхронизация: 2022-09-07
Рыночная капитализация
$162.94K
Изменение (1 день)
2.17%
Изменение (1 год)
0.00%
Страна
US
Торговля Brickell Biotech, Inc. (BBI)

Категория

История дивидендной доходности для Brickell Biotech, Inc. (BBI)
Дивидендная доходность (TTM) компании Brickell Biotech, Inc. (тикер: BBI) на 2026 составляет: 0
Средняя дивидендная доходность за последние 5 лет: 0.00%
История дивидендной доходности компании Brickell Biotech, Inc. (BBI) с 2026 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
Недостаточно данных для указанных дат.
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE